+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Antimicrobial Therapeutics Market Size was valued at USD 96.0 Billion in 2022. The Antimicrobial Therapeutics market industry is projected to grow from USD 101.20 Billion in 2023 to USD 153.00 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.80% during the forecast period (2023 - 2032). The pharmaceutical sector is successful due to recent drug approvals, a robust pipeline, government agency activities, and expanding knowledge of microbial diseases, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The market is primarily driven by favorable regulatory policies and the rising occurrence of infectious diseases. Furthermore, it is projected that an increase in infections with antibiotic resistance spurred on by misuse or overuse of antibiotics will alter prescription trends for cutting-edge drugs to treat bacterial infections. Over 2.8 million infections that are resistant to antibiotics are thought to exist in the US, according to the CDC. The resistance rate for illnesses including Enterobacteriaceae, P. aeruginosa, and K. pneumoniae is high in wealthy countries, averaging 40%.
Pharmaceutical companies' increased attempts to find novel cures for infectious diseases are predicted to boost the market during the forecasted period. According to Pew Charitable Trust, around 41 potential substances were being studied in December 2019 for the treatment of harmful bacterial infections. It is projected that 17 of these 41 experimental drugs will be on sale during the projection period since they are either in the third stage of clinical trials or have submitted an NDA for approval. In the second half of 2019, the American FDA authorized the use of four new antibiotic drugs. Furthermore, it is envisaged that beneficial government regulations, such the GAIN Act and REVAMP Act, will speed the clearing procedure internationally. The release of novel antibiotic drugs is anticipated to encourage market increase over the course of the projected timeframe.
The need for antibiotics has increased significantly as a result of the increase in infectious disease incidences. The high incidence of infectious diseases such lower respiratory infections, pneumonia, malaria, and tuberculosis is another driver propelling the market's rise. In order to expedite the approval process and research funding, government and non-government entities are being compelled to spend in R&D programs, enhance the development of novel antibiotics, and develop supportive regulatory standards. For instance, BARDA has assisted many companies in working with the government to create cutting-edge medicines for infectious diseases. Thus, driving the Antimicrobial Therapeutics market revenue.
The global Antimicrobial Therapeutics market segmentation, based on Application, includes antiviral, antibacterial, antifungal, and antiparasitic. The antiviral market sector had the most market share in 2022. The segment's growth is being driven by the increasing occurrence of viral illnesses such the flu, hepatitis, COVID-19, and HIV/AIDS. Remdesivir was one of the chemicals being researched for the treatment of COVID-19, hence the rise of pandemic diseases like COVID-19 increased the need for antiviral drugs. Therefore, during the projection period, the global spread of viral illnesses is anticipated to support market expansion.
The global Antimicrobial Therapeutics market segmentation, based on End User, includes pharmacies, hospitals and clinics, and research and academic institutes. In 2022 the pharmacy industry held a higher share of the market. Although the economic possibilities for antibacterial drugs are already constrained by the relatively narrow pharmacological pipeline, the market for these products is growing substantially. But it is anticipated that as a result of the rigorous efforts made by the governments of many countries, particularly in Europe and North America, the development of branded pharmaceuticals would increase. To help in the development of new antibacterial drugs, the U.S. Food and Drug Administration announced in February 2021 the creation of the Antibacterial Drug Development Task Force at the Center for Drug Evaluation and Research (CDER). In the future, pharmacies will also serve as a full-fledged distribution channel, supporting prescription validity and facilitating same-day or next-day delivery. Recent World Health Organization research indicates that one in ten of the medical supplies in use in low- and middle-income countries are either poor or phony.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
By region, Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Antimicrobial Therapeutics Market dominated this market in 2022 (45.80%). Both the regulatory environment and the healthcare infrastructure in these markets are highly developed. The rise of infectious diseases and increased government healthcare spending are two major factors driving the North American industry. The United States government is implementing a number of steps, including stepping up R&D for innovative medications to treat infectious diseases and launching antibiotic stewardship programs. Further, In the North American area, the U.S. Antimicrobial Therapeutics market had the biggest market share, while the Canada Antimicrobial Therapeutics market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The largest market share is accounted for by the antimicrobial therapeutics market in Europe. The rapid development of the healthcare infrastructure in a number of European countries, the rising investment in research and development activities, and the rising number of hospitals in the region are the main factors affecting demand for these pharmaceuticals in the European market. Further, In the European region, the German Antimicrobial Therapeutics market had the biggest market share, and the U.K. Antimicrobial Therapeutics market had the quickest rate of growth.
The Asia Pacific Antimicrobial Therapeutics market, is expected to register fastest growth from 2023 to 2032. This can be seen in the rising use of antibiotics, growth in infectious diseases, and rise in government initiatives to develop novel treatments to treat infections with drug resistance. The regional market also benefits from the presence of generic rivals. India and China are the two biggest markets in the area for antibiotics. Unrestricted sales and excessive antibiotic usage are the key forces behind market expansion in these nations. Moreover, In the Asia-Pacific region, the Indian Antimicrobial Therapeutics market had the quickest rate of growth while China's Antimicrobial Therapeutics market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Antimicrobial Therapeutics market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Antimicrobial Therapeutics sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Aerospace Foam industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Antimicrobial Therapeutics sector. Major players in the Antimicrobial Therapeutics market, including AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio, Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd., are attempting to increase market demand by investing in research and development operations.
Global generic pharmaceutical firm Sandoz Inc., a unit of Novartis AG, develops, produces, sells, and distributes a variety of prescription drugs, protein products, and biosimilars. Additionally, Sandoz provides other businesses with intermediary goods including active pharmaceutical ingredients (APIs) and services for biotechnology manufacture. For a variety of therapeutic fields, including dermatology, cancer, cardiovascular, respiratory, metabolic, central nervous system, pain management, ophthalmology, gastrointestinal, and hormone therapies, the company provides active ingredients and completed dosage forms. Wholesalers, pharmacies, hospitals, and other healthcare facilities receive Sandoz's products for distribution. With its headquarters in Princeton, New Jersey, the United States, Sandoz has improved its market share by acquiring GSK's cephalosporin division in February 2021.
A biopharmaceutical firm called Pfizer Inc. is engaged in the research, development, production, and marketing of medical products. Treatments for a range of ailments are included in Pfizer's product line, including those for cancer, inflammation, immunological disorders, rare diseases, women's health, metabolic disorders, cardiovascular diseases, and pain management. Additionally, the business provides contract manufacturing services, sterile injectable drugs, biosimilars, and active pharmaceutical ingredients (APIs). A definitive deal was signed between Pfizer and Mylan in July 2019, and as a result, Viatris was born. Pfizer has been able to increase its global reach thanks to this deal.
· AbbVie Inc.
· Astellas Pharma Inc.
· Bavarian Nordic AS
· Biocidium Biopharmaceuticals Inc.
· Bristol Myers Squibb Co.
· Cadila Pharmaceuticals Ltd.
· CSL Ltd.
· Emergent BioSolutions Inc.
· F. Hoffmann La Roche Ltd.
· Gilead Sciences Inc.
· GlaxoSmithKline Plc
· Inovio Pharmaceuticals Inc.
· Johnson and Johnson Services Inc.
· Merck and Co. Inc.
· Mitsubishi Tanabe Pharma Corp.
· Novartis AG
· Novavax Inc.
· Pfizer Inc.
· Sanofi SA
· Wockhardt Ltd.
September 2021: According to a statement from Myovant Sciences and Pfizer Inc., the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREER (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe pain brought on by endometriosis.
July 2021: AstraZeneca established a partnership with Regeneron to undertake research, create, and commercialize small molecule drugs against the GPR75 target with the potential to treat obesity and related co-morbidities
· Antiviral
· Antibacterial
· Antifungal
· Antiparasitic
· Pharmacies
· Hospitals and Clinics
· Research and Academic Institutes
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
Report Scope
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 96.0 Billion |
|
Market Size 2023 |
USD 101.20 Billion |
|
Market Size 2032 |
USD 153.00 Billion |
|
Compound Annual Growth Rate (CAGR) |
5.80% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Application, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio, Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd. |
|
Key Market Opportunities |
Growing collaborations for development of antibiotics |
|
Key Market Dynamics |
Recent drug approvals and a robust pipeline, initiatives from government agencies in the pharmaceutical industry, and rising awareness about microbial diseases |
The global Antimicrobial Therapeutics Market was valued at USD 96.0 billion in 2022, and it is estimated to reach USD 153.00 billion by 2032.
The global market is projected to grow at a CAGR of 5.80% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio, Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd.
The Antiviral Application dominated the market in 2022.
The Pharmacies End User had the largest share in the global market.
Report Code :
RL6567
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst